Anifrolumab

Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research[1][2].

Product Specifications

CAS Number

[1326232-46-5]

Product Name Alternative

MDX-1333; MEDI-546

UNSPSC

12352203

Target

IFNAR

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anifrolumab.html

Purity

99.79

Solubility

10 mM in DMSO

Smiles

[Anifrolumab]

Molecular Weight

(144.92 kDa)

References & Citations

[1]Furie R, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69 (2) :376-386.|[2]Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5 (1) :e000261.